

Sanofi pasteur cordially invites you to an educational program titled:

Fluzone[®] High-Dose (Influenza Virus Vaccine) What You Need To Know

Presented by:

David P. Greenberg, M.D.

Senior Director, Scientific and Medical Affairs
Sanofi Pasteur

Two Web / Audio Conferences

Tuesday, August 10, 2010

12:30 - 1:30pm - Eastern Time

To view presentation slides for August 10th, click on following URL:

<http://attewc.webex.com/attewc/onstage/g.php?d=881991357>

&

Wednesday, August 11, 2010

3:00 - 4:00pm - Eastern Time

To view presentation slides for August 11th, click on following URL:

<http://attewc.webex.com/attewc/onstage/g.php?d=883661011>

If necessary, right click on URL and select "open hyperlink"

To hear the presentation for both dates, please call:

(800) 230-1951

For technical support during or before the presentation, call (888) 793-6118

Program Objectives:

- 1). Understand that as a result of immunosenescence, persons 65 years of age and older do not respond to influenza vaccines as well as younger adults, and these older individuals suffer disproportionately from influenza-related morbidity and mortality despite relatively high immunization rates
- 2). Describe the rationale for developing Fluzone High-Dose vaccine and FDA licensure of this vaccine using the Accelerated Approval Process for products intended to meet an unmet medical need for serious and life-threatening diseases
- 3). Review safety and immunogenicity data from a recent phase III clinical trial, including data demonstrating that Fluzone High-Dose vaccine induces significantly higher antibody responses against all 3 influenza virus strains compared with standard-dose Fluzone vaccine among people 65 years of age and older

Please RSVP your preferred date by Friday, August 6th, 2010 to:

Les Tice

les.tice@sanofipasteur.com

In accordance with sanofi pasteur's policies and the PhRMA Code of Interaction with Healthcare Professionals, attendance at this educational program is limited to health-care professionals.